Posted by Michael Wonder on 13 Jan 2022
CMS proposes Medicare coverage policy for monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease
11 January 2022 - Today, the Centers for Medicare & Medicaid Services released a proposed National Coverage Determination decision memorandum.
The proposed National Coverage Determination would cover FDA approved monoclonal antibodies that target amyloid for the treatment of Alzheimer’s disease through coverage with evidence development – which means that FDA approved drugs in this class would be covered for people with Medicare only if they are enrolled in qualifying clinical trials.
